

Viread® For Hepatitis B Registration In The Developing World

Approved

1. Albania	July 2011	20. Egypt	March 2012	39. Palau	December 2010
2. Anguilla	June 2011	21. Fiji	December 2010	40. Panama	February 2012
3. Antigua and Barbuda	June 2011	22. Georgia	June 2011	41. Paraguay	September 2011
4. Armenia	September 2011	23. Grenada	June 2011	42. Peru	June 2011
5. Aruba	September 2011	24. Guatemala	June 2011	43. Saint Kitts and Nevis	June 2011
6. Azerbaijan	May 2011	25. Haiti	September 2012	44. Saint Lucia	June 2011
7. Bahamas	June 2011	26. Honduras	July 2012	45. Saint Vincent and the Grenadines	June 2011
8. Bangladesh	June 2011	27. India	December 2011	46. Samoa	December 2010
9. Barbados	June 2011	28. Iran	April 2012	47. Solomon Islands	December 2010
10. Belize	June 2011	29. Kazakhstan	May 2012	48. Thailand	June 2013
11. Bhutan	November 2012	30. Kiribati	December 2010	49. Timor-Leste	December 2010
12. Bolivia	September 2011	31. Kosovo	June 2011	50. Tonga	December 2010
13. Bosnia and Herzegovina	June 2012	32. Kyrgyzstan	July 2012	51. Turk and Caicos	June 2011
14. British Virgin Islands	June 2011	33. Lao, People's Dem. Rep	January 2013	52. Tuvalu	December 2010
15. Cambodia	April 2011	34. Moldova	January 2013	53. Vietnam	September 2011
16. Cuba	June 2011 ✓	35. Montserrat	June 2011	54. Vanuatu	*December 2010
17. Curacao	October 2011	36. Myanmar	December 2012	55. Ukraine	September 2012
18. Dominica	June 2011	37. Nauru	December 2010	56. Uzbekistan	May 2011
19. Ecuador	August 2012	38. Pakistan	January 2013		

Filed

1. China	January 2013	4. Guyana	January 2012	7. Syria	December 2012
2. Dominican Republic	March 2012	5. Jamaica	June 2011	8. Tajikistan	August 2011
3. El Salvador	June 2011	6. Philippines	March 2013	9. Turkmenistan	July 2011

Pending Submission

1. Afghanistan	15. Congo, Dem. Rep. of the	29. Kenya
2. Algeria	16. Côte d'Ivoire	30. Lesotho
3. Angola	17. Djibouti	31. Liberia
4. Belarus	18. Equatorial Guinea	32. Libya
5. Benin	19. Eritrea	33. Madagascar
6. Botswana	20. Ethiopia	34. Malawi
7. Burkina Faso	21. Gabon	35. Malaysia
8. Burundi	22. Gambia	36. Maldives
9. Cameroon	23. Ghana	37. Mali
10. Cape Verde	24. Guinea	38. Mauritania
11. Central African Republic	25. Guinea-Bissau	39. Mauritius
12. Chad	26. Indonesia	40. Mongolia
13. Comoros	27. Iraq	41. Montenegro
14. Congo	28. Jordan	42. Morocco

Pending Submission (cont.)

43. Mozambique	52. Senegal	61. Swaziland
44. Namibia	53. Seychelles	62. Tanzania, U. Rep. of
45. Nepal	54. Sierra Leone	63. Togo
46. Nicaragua	55. Somalia	64. Trinidad and Tobago
47. Niger	56. South Africa	65. Tunisia
48. Nigeria	57. South Sudan	66. Uganda
49. Papua New Guinea	58. Sri Lanka	67. Yemen
50. Rwanda	59. Sudan	68. Zambia
51. São Tomé and Príncipe	60. Suriname	69. Zimbabwe

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Pending Submission: Dossier has not been submitted to date; standard dossier filed - specific documentation required in order to further application process; or all relevant documentation provided to distributor for in-country submission (submission may be pending translation into local language).

Italicized: Countries where approval is granted via Notification and/or Import Permit. Notification refers to documentation, other than a registration dossier, that is reviewed and approved by the Health Authority; an Import Permit is an authorization by a competent authority for the importation of product into the country.

Check Mark (✓) Product available through distributor.

Note

There can be no guarantee that marketing approval for Complera®/Eviplera® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.